新天药业 (002873)

Guiyang Xintian Pharmaceutical Co.,Ltd.

ASZ

Tags

Generic DrugsImmunotherapyMicro Cap StocksNew Private Equity HoldingsShareholder ReductionChinese Med. IICSI 2000 IndexSZSE Medicine Equal Weight IndexCSI Circulation IndexCSI All-share IndexShenzhen A-Share Pharmaceutical IndexCSI All-share Pharmaceutical Sector IndexNew Virus PreventionCOVID-19 PreventionConvertible Bond IssuersInternal Employee SharesExpected Loss/DeclineQFII HoldingsFund Heavy HoldingsJune 2022 Lock-up ExpirySME Board Composite IndexSZSE Composite IndexNew IndexEmerging Industries Composite IndexManufacturing IndexCSI A-Share IndexCNI A-Share IndexChina United Quality Growth IndexPrivate Enterprise Development IndexGuizhou

K-Line Chart

No K-line data available

Company NameGuiyang Xintian Pharmaceutical Co., Ltd.
Listing Date2017-05-19
Issue Price18.41RMB
Registered Capital24410.380610k RMB
Legal RepresentativeDong Dalun
Registered AddressNo. 114 Xintian Avenue, Guiyang National High-Tech Industrial Development Zone, Guiyang City, Guizhou Province
IndustryTraditional Chinese Medicine II
Main BusinessResearch, development, production, and sales of traditional Chinese medicine products for urological diseases, gynecological diseases, and other complex diseases, providing patients with safe and effective products.
Company ProfileGuiyang Xintian Pharmaceutical Co., Ltd., established in August 1995, is located in the Guiyang National High-Tech Industrial Development Zone. It is a modern traditional Chinese medicine pharmaceutical enterprise integrating research, production, and sales, with a registered capital of 51.66 million yuan and total assets of nearly 400 million yuan. In 2012, it achieved sales revenue of over 400 million yuan, employed nearly 1,000 people, and held over 50 drug production approvals. The company's factory site covers an area of more than 150 mu and has six GMP-certified production lines for hard capsules, mixtures, granules, gels, tablets, and syrups. It is recognized as a High-Tech Enterprise in Guizhou Province, a Key Support Unit in Guizhou Province, and a designated national ethnic medicine production enterprise.

Stock Details

1. Key Indicators

  • Total Shares(W): 24410.38
  • Circulating A-Shares(W): 23866.88
  • Earnings Per Share(RMB): 0.0663
  • Net Assets Per Share(RMB): 5.1753
  • Operating Revenue(W RMB): 55863.30
  • Total Profit(W RMB): 1667.16
  • Net Profit Attributable to Parent(W RMB): 1618.09
  • Net Profit Growth Rate(%): -73.47
  • Weighted Return on Equity(%): 1.35
  • Operating Cash Flow Per Share(RMB): 0.4750
  • Undistributed Profit Per Share(RMB): 2.3165
  • Capital Reserve Per Share(RMB): 1.1567

2. Main Business

The main business covers:

  • R&D, production, and sales of new Chinese patent medicines

3. Company Basic Information

  • Company Name: Guiyang Xintian Pharmaceutical Co., Ltd.
  • Listing Date: 2017-05-19
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 3 Gaoxin North Road, Wudang District, Guiyang City, Guizhou Province
  • Website: www.gyxtyy.com
  • Company Profile: According to the approval document Qian Fu Han [2001] No. 661 from the Guizhou Provincial People's Government, the company was established by converting the total audited net assets of RMB 40,573,340.31 as of August 31, 2001 (as per the audit report Shen Hua [2001] Shen Zi No. 398 issued by Shenzhen Dahua Tiancheng Certified Public Accountants) into 40.57 million shares at a 1:1 ratio, with the remaining RMB 3,340.31 credited to capital reserve. The company was transformed into Guiyang Xintian Pharmaceutical Co., Ltd. and obtained the Business License with registration number 5200001204533 on December 30, 2001.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shanghai Xintian Zhiyao Biotechnology Co., Ltd. Corporate Legal Person 7548.56 31.63
2 Morgan Stanley Health Industry Hybrid Securities Investment Fund A Class Fund 201.91 0.85
3 Guiyang Kaiyuan Biological Resources Development Co., Ltd. Corporate Legal Person 166.97 0.70
4 CITIC Securities Asset Management (Hong Kong) Limited - Client Funds Asset Management Plan 111.12 0.47
5 ChinaAMC CSI Traditional Chinese Medicine ETF Fund 105.97 0.44
6 Shanghai Yinye Investment Co., Ltd. - Yinye - Gongyu Theme Selection Phase 2 Private Securities Investment Fund Private Securities Investment Fund 100.00 0.42
7 Goldman Sachs & Co. LLC QFII 67.24 0.28

5. Concept Sectors

  • Immunotherapy
  • Generic Drugs
  • Hepatitis Concept
  • Innovative Drugs
  • Micro-Cap Stocks
  • Shareholder Reduction
  • New Private Placement

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information